Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Stephen Bagley(University of Pennsylvania), Zev A. Binder(University of Pennsylvania), Lamia Lamrani(Inserm), Eliana Marinari(University of Geneva), Arati Desai(University of Pennsylvania), MacLean P. Nasrallah(University of Pennsylvania), Eileen Maloney(University of Pennsylvania), Steven Brem(University of Pennsylvania), Robert A. Lustig(University of Pennsylvania), Goldie Kurtz(University of Pennsylvania), Michelle Alonso‐Basanta(University of Pennsylvania), Pierre‐Emmanuel Bonté(Inserm), Christel Goudot(Inserm), Wilfrid Richer(Inserm), Eliane Piaggio(Inserm), Shawn Kothari(Emory University), Léa Guyonnet(Institut Curie), Coralie L. Guérin(Institut Curie), Joshua J. Waterfall(Inserm), Suyash Mohan(University of Pennsylvania), Wei‐Ting Hwang(University of Pennsylvania), Oliver Y. Tang(Brown University), Meghan Logun(University of Pennsylvania), Meghna Bhattacharyya(Cooper Medical School of Rowan University), Kelly Markowitz(University of Pennsylvania), Devora Delman(University of Pennsylvania), Amy Marshall(University of Pennsylvania), E. John Wherry(Parker Institute for Cancer Immunotherapy), Sebastián Amigorena(Inserm), Gregory L. Beatty(University of Pennsylvania), Jennifer L. Brogdon(Novartis (United States)), Elizabeth O. Hexner(University of Pennsylvania), Denis Migliorini(University of Geneva), Cécile Alanio(Inserm), Donald M. O’Rourke(University of Pennsylvania)
Cited by 162Open Access